Please login to the form below

Not currently logged in
Email:
Password:

Shire pitching at adult ADHD product launch in 2017

Will have to first trial formulation in children to appease FDA

Shire BasingstokeThe FDA has agreed a regulatory route for Shire's attention deficit hyperactivity disorder (ADHD) product for adults, potentially opening up a lucrative new market for the company's franchise.

Most cases of ADHD are diagnosed in children, and the prevailing wisdom has been that in most cases symptoms resolve as patients reach maturity. However, the adult form of the disorder is also remarkably common, with an estimated prevalence of up to 5%, and is considered to be the most severe long-term outcome of this neurodevelopmental disorder.

Shire wants to develop a drug called SHP465 (triple-bead mixed amphetamine salts) for adult ADHD, but to satisfy the FDA will have to first carry out a trial of the formulation in children, as was first revealed by the company last October.

The company had initially hoped to launch the product later this year, but the new regulatory route means that a timeframe of 2017 is more likely. The first patient is due to be enrolled into the paediatric trial in August.

"Adult patients with ADHD represent the fastest growing segment of the overall ADHD patient population," said Shire in a statement.

Breaking into the adult ADHD - as well as a sideways move into binge-eating disorder with paediatric ADHD therapy Vyvanse (lisdexamfetamine) - could eventually double sales of Shire's psychiatric portfolio by 2020, according to chief executive Flemming Ornskov. 

Last year, the company's psychiatric drugs brought in around $2.2bn in sales and royalties, a little over a third of its total annual revenues of $6bn.

Adults already receive treatment for ADHD off-label using drugs such as Adderall and Adderall XR - both also based on mixed amphetamine salts - but it is though that a sizeable proportion use the long- and short-acting form sequentially in order to control symptoms throughout the day. 

SHP465 will provide 16 hours cover from a single tablet, extending from the morning into the evening, according to Shire, which also expects the new formulation to claim three years' additional market exclusivity in the US, extending its patent protection out to 2029.

Article by
Phil Taylor

8th April 2015

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics